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CORONARYIs Bare-Metal Stent Implantation
Still Justifiable in High Bleeding Risk
Patients Undergoing Percutaneous
Coronary Intervention?
A Pre-Specified Analysis From the ZEUS TrialSara Ariotti, MD,a,b Marianna Adamo, MD,b Francesco Costa, MD,b Athanasios Patialiakas, MD,c
Carlo Briguori, MD, PHD,d Attila Thury, MD, PHD,e Salvatore Colangelo, MD,f Gianluca Campo, MD,g
Matteo Tebaldi, MD,g Imre Ungi, MD, PHD,e Stefano Tondi, MD,h Marco Roffi, MD,i Alberto Menozzi, MD, PHD,j
Nicoletta de Cesare, MD,k Roberto Garbo, MD,f Emanuele Meliga, MD,l Luca Testa, MD, PHD,m
Henrique Mesquita Gabriel, MD,n Marco Ferlini, MD,o Pascal Vranckx, MD, PHD,p Marco Valgimigli, MD, PHD,a,b
for the ZEUS InvestigatorsABSTRACTOBJECTIVES This study sought to investigate the ischemic and bleeding outcomes of patients fulfilling high bleeding
risk (HBR) criteria who were randomized to zotarolimus-eluting Endeavor Sprint stent (E-ZES) or bare-metal stent
(BMS) implantation followed by an abbreviated dual antiplatelet therapy (DAPT) duration for stable or unstable
coronary artery disease.
BACKGROUND DES instead of BMS use remains controversial in HBR patients, in whom long-term DAPT poses safety
concerns.
METHODS The ZEUS (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates) is a multinational, ran-
domized single-blinded trial that randomized among others, in a stratified manner, 828 patients fulfilling pre-defined
clinical or biochemical HBR criteria—including advanced age, indication to oral anticoagulants or other pro-hemorrhagic
medications, history of bleeding and known anemia—to receive E-ZES or BMS followed by a protocol-mandated 30-day
DAPT regimen. The primary endpoint of the study was the 12-month major adverse cardiovascular event rate, consisting
of death, myocardial infarction, or target vessel revascularization.
RESULTS Compared with patients without, those with 1 or more HBR criteria had worse outcomes, owing to higher
ischemic and bleeding risks. Among HBR patients, major adverse cardiovascular events occurred in 22.6% of the E-ZES
and 29% of the BMS patients (hazard ratio: 0.75; 95% confidence interval: 0.57 to 0.98; p ¼ 0.033), driven by lower
myocardial infarction (3.5% vs. 10.4%; p < 0.001) and target vessel revascularization (5.9% vs. 11.4%; p ¼ 0.005) rates
in the E-ZES arm. The composite of definite or probable stent thrombosis was significantly reduced in E-ZES recipients,
whereas bleeding events did not differ between stent groups.
CONCLUSIONS Among HBR patients with stable or unstable coronary artery disease, E-ZES implantation provides
superior efficacy and safety as compared with conventional BMS. (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain
DES Candidates [ZEUS]; NCT01385319) (J Am Coll Cardiol Intv 2016;9:426–36) © 2016 by the American College of
Cardiology Foundation.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 5 , 2 0 1 6 Ariotti et al.
M A R C H 1 4 , 2 0 1 6 : 4 2 6 – 3 6 Zotarolimus Stent in High Bleeding Risk Patients
427AB BR E V I A T I O N S
AND ACRONYM S
BARC = Bleeding Academic
Research Consortium
BMS = bare-metal stent(s)
CI = confidence interval
DES = drug-eluting stent(s)




HBR = high bleeding risk
HR = hazard ratio
IQR = interquartile range
MACE = major adverse
cardiovascular event(s)
MI = myocardial infarctionD rug-eluting stents (DES) reduce the reste-nosis rates as compared to bare-metalstents (BMS) (1–3). However, an excessive
inhibition of neointimal formation with incomplete
endothelialization, observed in the first-generation
devices, has been associated with an increased risk
of very-late stent thrombosis (ST) after dual anti-
platelet therapy (DAPT) discontinuation (4,5).
Second-generation DES have been developed to over-
come safety concerns and maintain the efficacy
similar to first-generation DES. Yet, a minimum
course of 3- or 12-month DAPT duration is currently
mandated after implantation of newer-generation
DES according to current European or American
guidelines, respectively (6,7). As a consequence, the
use of DES instead of BMS remains controversial in
high bleeding risk (HBR) patients, in whom long-
term DAPT poses safety concerns.SEE PAGE 437
ST = stent thrombosis
TIMI = Thrombolysis In
Myocardial Infarction
TVR = target vessel
cularizationThe zotarolimus-eluting Endeavor Sprint stent
(E-ZES) is a hydrophilic polymer-based second-
generation device with a unique drug fast-release
profile (8), resulting in less powerful inhibition of
intimal hyperplasia, but also in a rapid and/or com-
plete stent strut coverage. This characteristic raises
the possibility that it might be feasible to shorten
DAPT duration while maintaining superior efficacy
compared with BMS (9). The ZEUS (Zotarolimus-
Eluting Endeavor Sprint Stent in Uncertain DES Can-
didates) study, which mandated a tailored DAPT
duration based on patients’ characteristics, showed a
lower incidence of major adverse cardiovascular
events (MACE) after E-ZES as compared with BMS in
uncertain DES recipients. More than 50% of the pa-
tients fulfilled at least 1 HBR criterion in this study,
and they were to be treated with a 30-day course of
DAPT only.
We sought to investigate: 1) the ischemic and
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METHODS
STUDY POPULATION. The design and main
study findings, including consistency of
study results across inclusion criteria, of the
ZEUS trial were previously reported (10,11).
Briefly, it was a multinational, randomized
single-blinded trial including patients with
at least 1 qualifying criterion among the
pre-specified uncertain DES recipients un-
dergoing elective, urgent, or emergent
percutaneous coronary intervention with
intended stent implantation. They were
randomly allocated 1:1 to receive E-ZES or a
thin-strut (thickness <100 mm) BMS followed
by a DAPT regimen independent of stent
type, but clinical-profile–driven. Randomiza-
tion was stratified based upon the presence or absence
of HBR status. Patients were deemed at HBR provided
they fulfil at least 1 of the pre-specified criteria,
including: age older than 80 years; clinical indication
for treatment with oral anticoagulant agents; recent
bleeding episode(s) that required medical attention or
hospitalization if the bleeding diathesis has not been
completely resolved; systemic conditions associated
with increased bleeding risk (e.g., hematological
disorders or any known coagulopathy determining
bleeding-diathesis, including prior or current throm-
bocytopenia, which was defined as platelet count
<100,000/mm3); known anemia, defined as repeatedly
documented hemoglobin <10 g/dl; and need for
long-term treatment with steroids or nonsteroidal
anti-inflammatory drugs.
The study was conducted in accordance with the
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428committees of all participating centers independently
approved the protocol, and all participants gave
written informed consent.
DEVICES AND THERAPY. The Endeavor stent (Med-
tronic Vascular, Minneapolis, Minnesota) is consti-
tuted by a cobalt-based alloy platform (91-mm strut
thickness) and a phosphorylcholine-polymer (4.8-mm)
loaded with zotarolimus at the dose concentration of
10-mg/mm stent length. The drug is eluted within
15 days of implantation, and concentration within
surrounding vascular tissue is not detected already at
30 days after stent deployment (8,9).
All commercially available thin-strut BMS were
allowed by the protocol. All patients received aspirin
and clopidogrel (300 to 600 mg orally as loading dose
followed by 75 mg/day), or prasugrel (60 mg as
loading dose followed by 10 or 5 mg/day) or ticagrelor
(180 mg as loading dose followed by 90 mg twice a
day). All HBR patients were treated with DAPT for a
pre-specified 30-day period after stent implantation.
In case of a staged procedure, DAPT had to be pro-
longed or restarted for 30 additional days. Patients
who were not eligible for DAPT were treated
with aspirin or P2Y12 inhibitor monotherapy. Unfrac-
tionated heparin or bivalirudin was used during
percutaneous coronary procedure according to
guideline-recommended regimens.FIGURE 1 HBR Criteria in the Study Population
The number of patients fulfilling each high bleeding risk (HBR) criterion i
HBR criteria, with 643 patients (78%) fulfilling 1, 330 (40%) 2, and 65
inflammatory drugs.STUDY ENDPOINTS AND FOLLOW-UP. The primary
endpoint of the ZEUS trial was MACE at 12 months,
defined as a composite of all-cause death, nonfatal
MI, and any target vessel revascularization (TVR).
Secondary efficacy endpoints were the composite
of death and MI; the composite of cardiovascular
death and MI; each component of the primary
endpoint; target lesion revascularization, ischemic
stroke; definite, probable, possible ST and the com-
posite of definite and probable ST. Secondary safety
endpoints comprised bleeding events according to
both Bleeding Academic Research Consortium (BARC)
and Thrombolysis In Myocardial Infarction (TIMI)
classifications. All study endpoint definitions were
previously reported (11).
Thirty-day and 6- and 12-month follow-up visits
were performed according to study protocol in order
to assess potential adverse events and compliance
with medications and to record a 12-lead
electrocardiogram.
All endpoints were confirmed on the basis of the
documentation collected at each site and were cen-
trally adjudicated by the clinical events committee,
whose members were unaware of treatment
assignment.
STATISTICAL ANALYSIS. In this pre-specified anal-
ysis of the ZEUS trial, categorical variables weres shown in decreasing order. There was a considerable overlap among
(8%) $3 HBR qualifying features. NSAID ¼ nonsteroidal anti-




(n ¼ 424) p Value
Age, yrs
Median 80.5 80.4 0.83
Interquartile range 72.3–84.4 72.8–84.9
Female 145 (35.9) 150 (35.4) 0.89
Body mass index, kg/m2
Median 26 26 0.96
Interquartile range 24–29 24–29
Diabetes 117 (29.0) 137 (32.3) 0.33
Hypertension 336 (83.2) 344 (81.1) 0.47
Hyperlipidemia 193 (47.8) 191 (45.0) 0.44
Current cigarettes use 45 (11.1) 44 (10.4) 0.36
Creatinine clearance, ml/min*
Median 54.3 54.8 0.90
Interquartile range 39.1–69.9 38.7–69.9
Patients with GFR <60 ml/min* 242 (61.3) 241 (59.5) 0.61
Patients with GFR <30 ml/min* 51 (12.9) 52 (12.8) >0.99
Patients on dialysis 6 (1.5) 14 (3.3) 0.11
Prior MI 114 (28.2) 117 (27.6) 0.88
Prior PCI 83 (20.5) 90 (21.2) 0.86
Prior CABG 38 (9.4) 39 (9.2) >0.99
Prior stroke or TIA 34 (8.4) 32 (7.5) 0.70
COPD 43 (10.6) 32 (7.5) 0.15
PAD 94 (23.3) 76 (17.9) 0.06
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429expressed as frequency and percentage, and compared
using the Fisher exact test, whereas continuous vari-
ables were expressed as median and interquartile
range, and compared with theWilcoxon rank sum test.
Estimation of the cumulative incidence of events
was performed by the Kaplan-Meier method, and
hazard ratios (HRs) with 95% confidence intervals
(CIs) and p values were calculated using the stratified
Cox regression model. The proportionality assump-
tions were checked by visual estimation after plotting
the log cumulative hazard versus (log) time at follow-
up after index procedure and by applying a test for
nonproportional hazards using the Schoenfeld re-
siduals, which failed to reject the null hypothesis that
event rate was affected by time (p ¼ 0.48). Sensitivity
analyses were performed testing the consistency of
study results in patients with only 1 or at least 2 HBR
criteria, as well as investigating the effect of allocated
stent type on outcomes according to each HBR crite-
rion when separately appraised.
A 2-sided p value <0.05 was considered significant.
All analyses were performed on the basis of the
intention-to-treat principle using SPSS version 21.0
(SPSS, Chicago, Illinois).Left ventricular ejection fraction†
Median 49 48 0.59
Interquartile range 40–55 40–55
Clinical presentation
Stable angina pectoris 140 (34.7) 147 (34.7) >0.99
Acute coronary syndrome
Unstable angina 69 (17.1) 72 (17.0) >0.99
Non–ST-segment elevation MI 133 (32.9) 140 (33.0) >0.99
ST-segment elevation MI 62 (15.3) 65 (15.3) >0.99
Angiographic features
Single-vessel disease 125 (30.9) 138 (32.5) 0.716
Double-vessel disease 144 (35.6) 146 (34.4)
Triple-vessel disease 132 (32.7) 139 (32.8)
Values are n (%), unless indicated otherwise. *Calculated in 395 patients in the BMS arm and in 405 patients in
the E-ZES arm. †Calculated in 380 patients in the BMS arm and in 397 patients in the E-ZES arm.
CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease; GFR ¼ glomerular
filtrate rate; HBR ¼ high bleeding risk; MI ¼ myocardial infarction; PAD ¼ peripheral artery disease; PCI ¼
percutaneous coronary intervention; TIA ¼ transient ischemic attack.RESULTS
STUDY POPULATION. From June 2011 to September
2012, a total of 5,288 patients were screened and
1,606 were finally randomized. A total of 828 patients
fulfilled 1 or more HBR criteria, of whom 425 (51.3%)
age >80 years, 311 (37.6%) had clinical indication
to oral anticoagulant (Online Table 1), 113 (13.6%)
reported previous or recent bleeding requiring hos-
pitalization or medical attention, 95 (11.5%) presented
bleeding diathesis, 68 (8.2%) had known anemia, and
25 (3.0%) were in need of long-term treatment with
steroids or nonsteroidal anti-inflammatory drugs.
There was a considerable overlap among HBR criteria,
with 643 patients (78%) fulfilling 1, 330 (40%) 2. and
65 (8%) $3 HBR qualifying features (Figure 1).
Baseline patient characteristics stratified according
to the presence or absence of HBR status are shown in
Online Tables 2 and 3.
Among HBR patients, of whom 424 (51.2%) were
randomized to receive E-ZES, and 404 (48.8%) to
BMS, baseline clinical and angiographic features were
well-matched between stent groups (Tables 1 and 2).
The median age was 80 years; diabetes was observed
in roughly one-third of the population, hypertension
in more than 80%, impaired kidney function in
approximately 60% of the patients, and 65% of pa-
tients had acute coronary syndrome at presentation(Table 1). One third of the patients underwent multi-
vessel intervention, and at least 1 complex lesion was
treated in approximately three-fourths of the patients
(Table 2).
DUAL ANTIPLATELET THERAPY. The duration of
DAPT—which largely consisted of aspirin and clopi-
dogrel—was almost 5-fold shorter in patients with HBR
criteria (median [interquartile range]: 30 [20 to 30]
days) as compared with those without HBR criteria
(median [interquartile range]: 174 [30 to 190] days;
p < 0.0001).




(n ¼ 424) p Value
Treated lesions, n
Median 1 1 0.82
Interquartile range 1–2 1–2
$2 Treated lesions* 154 (38.1) 151 (35.7) 0.47
Multivessel intervention 130 (32.2) 141 (33.3) 0.77
LAD treated 196 (48.5) 234 (55.2) 0.06
CFX treated 155 (38.4) 141 (33.3) 0.13
RCA treated 161 (39.9) 162 (38.2) 0.67
LMCA treated 27 (6.7) 26 (6.1) 0.78
SVG treated 6 (1.5) 8 (1.9) 0.79
At least 1 complex (type B2 or C) lesion 310 (76.7) 321 (75.7) 0.75
Total ACC/AHA score†
Median 7 7 0.94
Interquartile range 4–11 4–11
Stents implanted, n
Median 1 1 >0.99
Interquartile range 1–2 1–2
Length of stent, mm
Median 28 30 0.96
Interquartile range 18–46 18–44
Mean stent diameter, mm‡
Median 3 3 0.14
Interquartile range 2.75–3.50 2.75–3.25
Patients receiving $2 stents 182 (45.0) 191 (45.0) >0.99
Patients receiving $3 stents 73 (18.1) 77 (18.2) >0.99
Patients with overlapping stents 103 (25.5) 106 (25.0) 0.87
Quantitative coronary analysis
Lesion length, mm§ 16.88  10.44 16.44  10.64 0.28
Reference vessel diameter, before, mm§ 2.65  0.59 2.67  0.61 0.90
Minimal lumen diameter, before, mm§ 0.89  0.48 0.88  0.51 0.28
Stenosis, before, %§ 66  15 68  16 0.23
Reference vessel diameter, after, mm‡ 2.86  0.50 2.86  0.51 0.89
Minimal lumen diameter, after, mm§ 2.65  0.52 2.64  0.55 0.81
Stenosis, after, %§ 7.4  8.6 7.5  11.4 0.47
Drug therapy at discharge
Aspirin 377 (93.3) 386 (91.0) 0.25
P2Y12 inhibitor 387 (95.8) 410 (96.7) 0.58
ACE inhibitor 234 (57.9) 240 (56.6) 0.73
Beta-blocker 307 (76.0) 299 (70.5) 0.08
Statin 321 (79.5) 347 (81.8) 0.43
Oral anticoagulation 96 (23.8) 100 (23.6) >0.99
Proton pump inhibitork 290 (71.8) 293 (69.4) 0.49
Drug therapy at 30 days
Aspirin 373 (92.3) 383 (90.3) 0.33
P2Y12 inhibitor 364 (90.1) 389 (91.7) 0.47
ACE inhibitor¶ 213 (52.7) 242 (57.1) 0.40
Beta-blocker¶ 297 (73.5) 297 (70.0) 0.54
Statin¶ 303 (75.0) 336 (79.2) 0.25
Oral anticoagulation 100 (24.8) 97 (22.9) 0.81
Proton pump inhibitor# 267 (69.0) 270 (66.5) 0.49
Continued on the next page
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430Among HBR patients, 14 (3%) patients in each stent
group received treatment with a single antiplatelet
agent after stent implantation; among those who
received DAPT, treatment was stopped within the first15, 30, and 60 days in 5 (1.2%), 151 (37.4%), and 291
(72.0%) patients in the BMS and 10 (2.4%), 245 (57.8%),
and 323 (76.2%) in the E-ZES group, respectively (p <
0.001). Reasons for prolonging DAPT beyond 30 days
included planned or unplanned procedures in de novo
lesions, which were evenly distributed between stent
groups, or need for reintervention in previously
instrumented coronary segments, which explained
the longer DAPT duration in the BMS group.
BLEEDING RISK CRITERIA AND OUTCOMES. Any
actionable BARC bleeding was almost 2-fold higher in
patients with (7.7%) as compared with those without
(3.9%; HR: 2.32; 95% CI: 1.49 to 3.62; p < 0.001) at
least 1 HBR criterion whereas major BARC (4.2% vs.
1.5%; HR: 2.93; 95% CI: 1.51 to 5.70; p ¼ 0.001) and
major or minor TIMI bleeding (2.8% vs. 1.0%; HR:
2.87; 95% CI: 1.28 to 6.41; p ¼ 0.011) were almost
three-fold greater in the former group. There was
evidence of an additive effect on bleeding outcomes
with respect to the presence of only 1 or more than 1
HBR features (Figure 2).
The cumulative risk of death, MI or TVR was
doubled in HBR (25.7% vs. 13.5%; p < 0.001) as
compared with other patients, driven by higher rates
of death (16.5% vs. 5.7%; p < 0.001) or MI (6.9% vs.
4.0%; p ¼ 0.012). Definite or probable ST was also
increased in HBR patients (4.3% vs. 1.7%; p ¼ 0.002).
When adjustment was implemented for baseline
imbalances, residual bleeding (BARC type 2, 3, or 5
HR: 1.33, 95% CI: 0.75 to 2.36, p ¼ 0.332; BARC type 3
or 5 HR: 2.05, 95% CI: 0.84 to 4.98, p ¼ 0.114; TIMI
major or minor HR: 2.15, 95% CI: 0.73 to 6.29,
p ¼ 0.163) and mortality (adjusted HR: 1.46; 95% CI:
0.95 to 2.25; p ¼ 0.083) risks no longer differed.
STENT TYPES AND OUTCOMES IN HBR PATIENTS.
At 12 months, the primary endpoint occurred in 96
(22.6%) patients in the E-ZES and in 117 (29%) patients
in the BMS group (HR: 0.75; 95% CI: 0.57 to 0.98;
p ¼ 0.033), owing to lower MI (3.5% vs. 10.4%;
HR: 0.33; 95% CI: 0.18 to 0.60; p < 0.001) and TVR
(5.9% vs. 11.4%; HR: 0.50; 95% CI: 0.30 to 0.80; p ¼
0.005) rates in the E-ZES compared with BMS cohort
(Figure 3, Table 3). The composite of death and MI
(18.4% vs. 24.8%; HR: 0.72; 95% CI: 0.53 to 0.96;
p ¼ 0.027) as well as cardiovascular death or MI
(14.6% vs. 20.3%; HR: 0.70; 95% CI: 0.50 to 0.97;
p ¼ 0.032) were lower in the E-ZES group, whereas
mortality did not differ (Table 3). Definite or probable
ST (2.6% vs. 6.2%; HR: 0.42; 95% CI: 0.21 to 0.85;
p ¼ 0.016) and definite, probable or possible ST (6.6%
vs. 10.6%; HR: 0.61; 95% CI: 0.38 to 0.98; p ¼ 0.042)
were respectively more than halved or reduced by





(n ¼ 424) p Value
Dual antiplatelet therapy duration
Median 31 30 0.009
Interquartile range 30–177 30–53
Range 0–365 0–365
Values are n (%) or mean  SD, unless indicated otherwise. *Calculated in 404 patients in the BMS arm and in
423 in the E-ZES arm. †Calculated in 402 patients in the BMS arm and in the 422 in the E-ZES arm. ‡Calculated in
395 patients in the BMS arm and in the 416 patients in the E-ZES arm. §Calculated in 396 patients in the BMS arm
and in 422 patients in the E-ZES arm. kCalculated in 404 patients in the BMS arm and in 422 in the E-ZES arm.
¶Calculated in 389 patients in the BMS arm and in 407 patients in the E-ZES arm. #Calculated in 387 patients in
the BMS arm and in the 406 patients in the E-ZES arm.
ACC/AHA ¼ American College of Cardiology/American Heart Association; ACE ¼ angiotensin-converting
enzyme; HBR ¼ high bleeding risk; LAD ¼ left anterior descending coronary artery, CFX ¼ circumflex coronary
artery, RCA ¼ right coronary artery, LMCA ¼ left main coronary artery, SVG ¼ saphenous vein graft.
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431Interestingly, the occurrence of ST appeared evenly
distributed in the BMS group when considering the on
versus off-DAPT follow-up duration, whereas only 1
of 11 ST cases in patients allocated to E-ZES occurred
while patients were off DAPT.
A trend towards a lower bleeding risk was noted
in the E-ZES cohort with respect to BARC 2, 3, or 5
events (6.1% vs. 9.4%; HR: 0.65; 95% CI: 0.39 to 1.07;
p¼0.089),whereasmajor BARCor TIMImajor orminor
events did not differ between stent groups (Table 3).
ADDITIONAL ANALYSES. The consistency of out-
comes with respect to the presence of a single or mul-
tiple HBR features is shown in Figure 4. The primary
endpoint outcomes in relation to each HBR criterion
are shown in Online Figure 1. A further sensitivity
analysis focusing on patients with atrial fibrillation
showed consistent findings (Online Figure 2).
DISCUSSION
Patients at HBR represent a well sizable portion of
coronary artery disease population undergoing
percutaneous coronary stenting. However, these pa-
tients have been largely excluded from major ran-
domized controlled trials evaluating different stent
types. Although multiple bleeding risk scores or sin-
gle individual risk factors for bleeding exist (12–14),
HBR status is rarely defined according to objective
risk criteria (15–17). The lack of standardized algo-
rithms for the identification of HBR patients hampers
comparability across studies and limit their external
validity in clinical practice.FIGURE 2 Bleeding Event Rates According to The Presence and Num
There was evidence of an additive effect on bleeding outcomes with resp
features; p value for trend <0.001. Vertical bars represent 95% confiden
Thrombolysis In Myocardial infarction.As a reflection of limited evidence for the use of
DES in this population, 6 of 10 (576 of 946) partici-
pants preferred BMS whereas only 1 out of 20 (44 of
946) responders vouched for the value of newer-
generation DES for HBR patients in a recent Euro-
pean survey (18).
MAIN STUDY FINDINGS. In the ZEUS trial, 828 pa-
tients fulfilling at least 1 pre-specified HBR criterion
were randomized to receive BMS or E-ZES, which is a
hydrophilic polymer-based second-generation device
with a unique drug, fast-release profile. In this
selected high-risk patient population, the study pro-
tocol mandated 30-day DAPT irrespective of the stent
type. The results of our study can be summarized as
follows:
 Patients at HBR, who have been selected according
to pre-specified objective criteria, displayed higherber of HBR Criteria
ect to the presence of only 1 or more than 1 high bleeding risk (HBR)
ce intervals. BARC ¼ Bleeding Academic Research Consortium; TIMI ¼
FIGURE 3 Clinical Outcomes in the HBR Population Treated With Zotarolimus-Eluting Stents Versus BMS
Rate of events for primary composite endpoint of death, myocardial infarction (MI), and target vessel revascularization (TVR) (A), MI (B), TVR
(C), or definite or probable stent thrombosis (D) at 12 months. BMS ¼ bare-metal stent(s); E-ZES ¼ zotarolimus-eluting Endeavor Sprint
stent(s); HBR ¼ high bleeding risk; HR ¼ hazard ratio.
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432risk of bleeding, consistently across all assessed
bleeding scales, which was proportionally greater
depending on the number of HBR criteria simul-
taneously fulfilled as compared with patients
without HBR features.
 Patients at HBR were also at higher MACE risk
as compared with patients who were not at HBR
status, driven by higher death and MI rates. ST was
almost 3-fold greater in patients with as compared
with those without HBR criteria. This observation
reinforces the notion that bleeding predictors
largely overlap with risk factors for ischemic com-
plications and highlights the challenge of identi-
fying a safe and effective anti-thrombotic treatment
in this patient population in clinical practice. HBR patients derived benefits in terms of
reductions of MACE, MI, TVR, and ST when treated
with E-ZES as compared with BMS, which is
consistent with study results observed in the over-
all population (11). At sensitivity analyses, results
remained entirely consistent focusing on patients
who displayed 2 or more HBR features, or evalu-
ating each HBR criterion separately. A further
analysis restricted to patients with atrial fibrilla-
tion, which was the most frequent indication to oral
anticoagulation, confirmed overall study findings.
 Despite comparable protocol-mandated DAPT du-
rations in both stent groups, cumulative treatment
duration with aspirin and P2Y12 inhibitor was
significantly longer in BMS as compared with E-ZES






(95% Confidence Interval) p Value
Primary efficacy endpoint
Death for any cause, myocardial infarction,
or target vessel revascularization
117 (29.0) 96 (22.6) 0.745 (0.568–0.977) 0.033
Secondary efficacy endpoints
Death for any cause or myocardial infarction 100 (24.8) 78 (18.4) 0.715 (0.531–0.963) 0.027
Death for cardiovascular cause or myocardial infarction 82 (20.3) 62 (14.6) 0.695 (0.499–0.968) 0.032
Death for any cause 70 (17.3) 67 (15.8) 0.913 (0.652–1.278) 0.595
Death for cardiovascular cause 51 (12.6) 50 (11.8) 0.931 (0.629–1.378) 0.720
Myocardial infarction 42 (10.4) 15 (3.5) 0.331 (0.184–0.598) <0.001
Target vessel revascularization 46 (11.4) 25 (5.9) 0.495 (0.304–0.806) 0.005
Target lesion revascularization 45 (11.1) 22 (5.2) 0.443 (0.266–0.739) 0.002
Ischemic stroke 11 (2.7) 5 (1.2) 0.432 (0.150–1.245) 0.120
Definite stent thrombosis* 10 (2.5) 4 (0.9) 0.381 (0.119–1.217) 0.103
Probable stent thrombosis* 15 (3.7) 7 (1.7) 0.448 (0.182–1.099) 0.079
Possible stent thrombosis* 18 (4.5) 17 (4.0) 0.870 (0.448–1.689) 0.681
Definite or probable stent thrombosis* 25 (6.2) 11 (2.6) 0.419 (0.206–0.853) 0.016
Definite, probable, or possible stent thrombosis* 43 (10.6) 28 (6.6) 0.610 (0.379–0.983) 0.042
Safety endpoints
TIMI classification
Major or minor 13 (3.2) 10 (2.4) 0.734 (0.322–1.674) 0.462
Major 10 (2.5) 6 (1.4) 0.318
Minor 3 (0.7) 4 (0.9) >0.99
Requiring medical attention 25 (6.2) 16 (3.8) 0.148
BARC classification†
Type 5 or 3 20 (5.0) 15 (3.5) 0.718 (0.368–1.404) 0.333
Type 5, 3, or 2 38 (9.4) 26 (6.1) 0.648 (0.393–1.068) 0.089
Type 5 4 (1.0) 2 (0.5) 0.441
Type 5A 3 (0.7) 1 (0.2) 0.362
Type 5B 1 (0.2) 1 (0.2) >0.99
Type 4 0 0 —
Type 3 16 (4.0) 13 (3.1) 0.572
Type 3A 5 (1.2) 2 (0.5) 0.276
Type 3B 9 (2.2) 10 (2.4) >0.99
Type 3C 2 (0.5) 1 (0.2) 0.616
Type 2 18 (4.5) 11 (2.6) 0.185
Values are n (%), unless indicated otherwise. *Stent thrombosis was defined according to the criteria of the Academic Research Consortium. †Type 5 refers to fatal bleeding;
Type 4 are coronary artery bypass–related bleedings; Type 3 bleedings are divided into 3A: overt bleeding plus hemoglobin drop of 3 to <5 g/dl or any transfusion with overt
bleeding, 3B: overt bleeding plus hemoglobin drop $5 g/dl or cardiac tamponed or bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemor-
rhoid) or bleeding requiring intravenous inotropes, 3C: intracranial hemorrhage or intraocular bleed compromising vision; Type 2 are any overt, actionable sign of hemorrhage
that does not fit the criteria for Types 3, 4, or 5, but does meet at least 1 of the following criteria: 1) requiring nonsurgical, medical intervention by a health care professional;
2) leading to hospitalization or increased level of care; and 3) prompting evaluation.
BARC ¼ Bleeding Academic Research Consortium; HBR ¼ high bleeding risk; TIMI ¼ Thrombolysis In Myocardial Infarction.
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433patients (Table 2), reflecting a higher TVR rate in
the former group of patients. Bleeding events
trended higher in the BMS compared with the
E-ZES groups, reflecting the longer DAPT after BMS
implantation.
COMPARISON WITH OTHER STUDIES. Randomized
controlled trials, which have so far compared DES
versus BMS, have recommended either a longer DAPT
regimen in the DES arm or a similarly prolonged
course of DAPT in BMS patients so to match the
extended course of therapy after DES (19,20). Hence,no study has so far disentangled the effects of DES
versus BMS from those offered by long-term DAPT.
The recent DAPT trial (21) that compared 30- versus
12-month duration of DAPT after stent implantation
in patients with stable or unstable coronary artery
disease, showed a significant decrease of very late
stent thrombosis and major adverse cardiovascular
and cerebrovascular events at 30 months after stent
implantation in the long-term DAPT arm. Yet, pa-
tients exposed to long-term DAPT also experienced a
borderline and significant increase in overall mortal-
ity at 30 and 33 months, respectively (21). Patients
FIGURE 4 Clinical Outcomes in Zotarolimus-Eluting Stents Versus BMS According to the Absence or Presence of a
Single or Multiple HBR Features
Patients without HBR criteria (No HBR), fulfilling 1 (HBR 1) or more than 1 (HBR>1) HBR criteria are shown, with HR and 95% confidence
intervals (CI), for the primary endpoint of all-cause death, MI, and TVR; death or MI; cardiovascular (CV) death or MI; MI; TVR; definite,
probable, or possible stent thrombosis and BARC type 2, 3, or 5 bleeding events among patients randomly assigned to either E-ZES or BMS
group. P-int ¼ p value for interaction. Abbreviations as in Figures 2 and 3.
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434who received BMS implantation, at discretion of the
treating physician were excluded from primary anal-
ysis, whereas only patients who were free from
ischemic and bleeding events after 12-month DAPT
were included in the study. Hence, patients at HBR
were excluded from the DAPT trial, and this study
was not designed to answer the question as to which
type of stent should be better used at the time of
intervention in patients fulfilling 1 or more HBR
criteria.
The WOEST (What is the Optimal antiplatElet &
Anticoagulant Therapy in Patients With Oral Anti-
coagulation and Coronary StenTing) trial (22)
included a total of total of 573 patients receiving oral
anticoagulant (w70% due to atrial fibrillation) who
were randomly assigned to clopidogrel alone(experimental treatment) or clopidogrel plus aspirin
(control treatment) for a period of 1 month after BMS
and 12 months after DES implantation. The primary
endpoint, consisting of any TIMI bleeding, was
significantly lower in the dual therapy group, largely
driven by minimal or minor bleeding, without an
increase in MI, TVR, stroke or stent thrombosis.
The ISAR-TRIPLE (Intracoronary Stenting and
Antithrombotic Regimen–Testing of a Six-WeekVersus
a six-Month Clopidogrel Treatment Regimen in Pa-
tients With Concomitant Aspirin and Oral Anticoagu-
lant Therapy Following Drug-Eluting Stenting) trial
(23) is the largest randomized trial investigating triple
therapy after DES implantation in patientswith clinical
indication to oral anticoagulant (w85% due to atrial
fibrillation). A total of 614 patients were randomly
PERSPECTIVES
WHAT IS KNOWN? The use of DES instead of BMS is matter of
debate in patients at high bleeding risk, in whom the benefits of
DES in terms of ischemic endpoints could be reduced by an in-
crease of bleeding events due to a long-term DAPT.
WHAT IS NEW? Our study demonstrated that the use of a
specific drug-eluting stent (zotarolimus-eluting Endeavor
Sprint stent), followed by a very short DAPT regimen, in a HBR
population with stable or unstable coronary artery disease,
provides superior efficacy and safety as compared with avail-
able BMS.
WHAT IS NEXT? Further research is needed to ascertain
whether an abbreviated DAPT regimen, as tested in our study,
can be safely implemented in patients receiving other types of
DES.
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435assigned to therapy with clopidogrel for 6 weeks (n ¼
307) or 6 months (n ¼ 307). The primary endpoint, a
composite of death, MI, ST, stroke, or TIMI major
bleeding, failed to show the anticipated superiority of
short- versus long-term triple therapy duration.
The ZEUS study is therefore the first randomized
controlled trial comparing 2 different stent types in
HBR patients after mandating a similarly short course
of DAPT. An interesting observation was that BMS
patients received a longer cumulative DAPT duration
as compared with those assigned to E-ZES, reflecting
the more frequent need to re-start DAPT after rein-
tervention for in-stent restenosis or ST. Given the
observation that long-term DAPT duration may be
paramount in patients receiving DES implantation for
the treatment of an in-stent restenosis (24), our cur-
rent findings may further justify the selection of a
safe DES over a BMS in this patient population to
minimize the risk of in-stent restenosis, which would
then require reintervention followed by a prolonged
course of DAPT.
The lower risk of MI or ST observed in patients
treated with E-ZES as compared to BMS, despite a
similarly short DAPT duration in both stent groups, is
consistent with the mounting evidence that lower
in-stent intimal hyperplasia may carry not only
greater efficacy (e.g., lower TVR), but also improved
safety (e.g., lower ST or stent-related MIs) (4, 25,26).
STUDY LIMITATIONS. By design, our study does not
address the topic of optimal DAPT duration after
stenting. On the other hand, the results of our
investigation challenge the current wisdom that BMS
is per se a safer coronary device as compared with
DES under a similarly short DAPT duration. Because
of the unique properties of the E-ZES, our results
should not be extrapolated to newer-generation DES
coated with the same or other antiproliferative agents
and diverse or no polymers. As for all substudies, type
I and type II errors are not corrected for. Hence, our
results should be hypothesis-generating. Further
research is needed to ascertain whether the tailored
DAPT regimen tested in our study can be safely
implemented in patients receiving other DES. The
recently reported LEADERS-FREE (A RandomizedClinical Evaluation of the BioFreedom Stent) trial
(27) largely reproduced our study findings in terms of
both better efficacy and safety in an HBR population
after the use of a drug-coated stent as compared with
the corresponding BMS. Therefore, it remains to be
seen whether other permanent or bioresorbable
polymer-based DES could be safely employed after a
30-day DAPT regimen.
CONCLUSIONS
Our study provides proof of concept that in HBR pa-
tients who undergo stent implantation, E-ZES as
compared with conventional BMS followed by 30-day
DAPT regimen provides superior efficacy and safety.
Future studies are needed to assess the tolerability
and safety of more contemporary DES when followed
by an abbreviated DAPT duration in this challenging
patient population.
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